Dereck Salisbury1, Tom Plocher2, Fang Yu3,4. 1. University of Minnesota School of Nursing, 5-160 WDH 1331, 308 Harvard St SE, Minneapolis, MN, 55455, USA. salis048@umn.edu. 2. Moai Technologies LLC, Minneapolis, MN, USA. 3. University of Minnesota School of Nursing, 5-160 WDH 1331, 308 Harvard St SE, Minneapolis, MN, 55455, USA. yuxxx244@umn.edu. 4. Arizona State University, Health North Suite 301, 550 North 3rd Street, Mail Code 3020, Phoenix, AZ, 85004, USA. yuxxx244@umn.edu.
Abstract
BACKGROUND:Subjective cognitive decline (SCD) is an early manifestation of Alzheimer's disease (AD) and offers a therapeutic window where interventions have strong potential to prevent or delay the progression of AD. Aerobic exercise and cognitive training represent two promising interventions for AD prevention, but their synergistic effect has yet to be assessed in persons with SCD. METHODS/ DESIGN: The purpose of this single-blinded, 3-parallel group randomized controlled trial is to test the synergistic efficacy of an exergame intervention (simultaneous moderate-intensity aerobic cycling and cognitive training) on cognition and aerobic fitness in community-dwelling older adults with SCD. The Exergames Study will randomize 96 participants on a 2:1:1 allocation ratio to 3-month exergame, cycling only, or attention control (stretching). Primary outcomes include global cognition and aerobic fitness, which will be assessed at baseline and after 3 months. The specific aims of the Exergames Study are to (1) determine the efficacy of the exergame in older adults with SCD and (2) assess the distraction effect of exergame on aerobic fitness. Data will be analyzed using ANOVA following intention-to-treat. DISCUSSION: This study will test the synergistic effects of exergame on cognition and aerobic fitness. It has the potential to advance prevention research for AD by providing effect-size estimates for future trials. TRIAL REGISTRATION: ClinicalTrials.gov NCT04311736 . Registered on 17 March 2020.
RCT Entities:
BACKGROUND: Subjective cognitive decline (SCD) is an early manifestation of Alzheimer's disease (AD) and offers a therapeutic window where interventions have strong potential to prevent or delay the progression of AD. Aerobic exercise and cognitive training represent two promising interventions for AD prevention, but their synergistic effect has yet to be assessed in persons with SCD. METHODS/ DESIGN: The purpose of this single-blinded, 3-parallel group randomized controlled trial is to test the synergistic efficacy of an exergame intervention (simultaneous moderate-intensity aerobic cycling and cognitive training) on cognition and aerobic fitness in community-dwelling older adults with SCD. The Exergames Study will randomize 96 participants on a 2:1:1 allocation ratio to 3-month exergame, cycling only, or attention control (stretching). Primary outcomes include global cognition and aerobic fitness, which will be assessed at baseline and after 3 months. The specific aims of the Exergames Study are to (1) determine the efficacy of the exergame in older adults with SCD and (2) assess the distraction effect of exergame on aerobic fitness. Data will be analyzed using ANOVA following intention-to-treat. DISCUSSION: This study will test the synergistic effects of exergame on cognition and aerobic fitness. It has the potential to advance prevention research for AD by providing effect-size estimates for future trials. TRIAL REGISTRATION: ClinicalTrials.gov NCT04311736 . Registered on 17 March 2020.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Verônica F Parreira; Tania Janaudis-Ferreira; Rachel A Evans; Sunita Mathur; Roger S Goldstein; Dina Brooks Journal: Chest Date: 2014-06 Impact factor: 9.410
Authors: George W Rebok; Karlene Ball; Lin T Guey; Richard N Jones; Hae-Young Kim; Jonathan W King; Michael Marsiske; John N Morris; Sharon L Tennstedt; Frederick W Unverzagt; Sherry L Willis Journal: J Am Geriatr Soc Date: 2014-01-13 Impact factor: 5.562
Authors: Patrick J Smith; James A Blumenthal; Benson M Hoffman; Harris Cooper; Timothy A Strauman; Kathleen Welsh-Bohmer; Jeffrey N Browndyke; Andrew Sherwood Journal: Psychosom Med Date: 2010-03-11 Impact factor: 4.312
Authors: Robert K Heaton; Natacha Akshoomoff; David Tulsky; Dan Mungas; Sandra Weintraub; Sureyya Dikmen; Jennifer Beaumont; Kaitlin B Casaletto; Kevin Conway; Jerry Slotkin; Richard Gershon Journal: J Int Neuropsychol Soc Date: 2014-06-24 Impact factor: 2.892
Authors: Jamie L Tait; Rachel L Duckham; Catherine M Milte; Luana C Main; Robin M Daly Journal: Front Aging Neurosci Date: 2017-11-07 Impact factor: 5.750
Authors: C Suo; M Fiatarone Singh; N Gates; W Wen; P Sachdev; H Brodaty; N Saigal; G C Wilson; J Meiklejohn; N Singh; B T Baune; M Baker; N Foroughi; Y Wang; Y Mavros; A Lampit; I Leung; M J Valenzuela Journal: Mol Psychiatry Date: 2016-03-22 Impact factor: 15.992